Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus lenalidomide vs rituximab plus placebo in relapsed/refractory indolent lymphoma (Phase 3)
2013-001245-14Phase 3Unknown
- Sponsor
- Celgene Corporation
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in indolent lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) comparing Rituximab plus lenalidomide with Rituximab plus placebo (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
lenalidomide
03
Conditions
indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2013-001245-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001245-14.